Differential effects of simvastatin and atorvastatin on high‐density lipoprotein cholesterol and apolipoprotein A‐I are consistent across hypercholesterolemic patient subgroups

Clinical Cardiology - Tập 26 Số 11 - Trang 509-514 - 2003
Michael H. Davidson1, Leiv Ose2, Jiří Fröhlich3, Russell Scott4, Carlos A. Dujovne5, Iván Darío Escobar6, Marcelo Chiara Bertolami7, Frank Cihon8, Darbie Maccubbin8, Michele Mercuri8
1Chicago Center for Clinical Research, Chicago, Illinois 60610, USA.
2Lipidklinikken, Oslo, Norway
3St. Paul Hospital, Vancouver, Canada
4Lipid and Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand
5Lipids, Heart Disease and Stroke Prevention Clinic, Radiant Research, Kansas City, Kansas, USA
6Asociacian Colombiana de Diabetes, Bogota, Colombia
7Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
8Merck Research Labs, Rahway, New Jersey, USA

Tóm tắt

AbstractBackground: In addition to lowering plasma levels of low‐density lipoprotein cholesterol (LDL‐C), statins also raise high‐density lipoprotein cholesterol (HDL‐C).Hypothesis: Recent studies have shown that treatment with simvastatin results in larger increases in HDL‐C than those seen with atorvastatin. The results of three clinical studies are analyzed, comparing the effects of simvastatin and atorvastatin on HDL‐C and apolipoprotein A‐I (apo A‐I) in the total cohort and in several subgroups of hypercholesterolemic patients. The three studies were all multicenter, randomized clinical trials that included simvastatin (20–80 mg) and atorvastatin (10–80 mg) treatment arms. The subgroup analyses performed were gender; age (<65 and ≥65 years); baseline HDL‐C (male: < 40 or ≥ 40 mg/dl; female: < 45 or ≥ 45 mg/dl), baseline LDL‐C (< 160 or ≥ 160 mg/dl), and baseline triglycerides (< 200 or ≥ 200 mg/dl).Results: Both drugs produced similar increases in HDL‐C levels at low doses; however, at higher drug doses (40 and 80 mg), HDL‐C showed a significantly greater increase with simvastatin than with atorvastatin (p< 0.05 to <0.001). Therefore, while HDL‐C remained consistently elevated across all doses of simvastatin, there appeared to be a pattern of decreasing HDL‐C with an increasing dose of atorvastatin. A similar negative dose response pattern was also observed with apo A‐I in atorvastatin‐treated patients, suggesting a reduction in the number of circulating HDL particles at higher doses. Both drugs reduced LDL‐C and triglycerides in a dose‐dependent fashion, with atorvastatin showing slightly greater effects. The differential effects of atorvastatin and simvastatin on HDL‐C and apo A‐I were observed for both the whole study cohorts and all subgroups examined; thus, no consistent treatment‐by‐subgroup interactions were observed.Conclusion: The data presented show that, across different hypercholesterolemic patient subgroups, simvastatin increases HDL‐C and apo A‐I more than atorvastatin at higher doses, with evidence of a negative dose response effect on HDL‐C and apo A‐I with atorvastatin, but not simvastatin.

Từ khóa


Tài liệu tham khảo

10.1056/NEJM199511163332001

10.1001/jama.279.20.1615

Scandinavian Simvastatin Survival Study Group, 1994, Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383

10.1056/NEJM199610033351401

10.7326/0003-4819-134-10-200105150-00007

10.1016/S0140-6736(02)09327-3

10.1001/jama.279.20.1643

10.1177/00912709922007642

10.1016/S0735-1097(00)00771-3

10.1016/S0002-9149(99)00153-8

10.1185/0300799039117026

10.1016/S0002-9149(00)00942-5

10.1002/clc.4960230910

10.1016/0002-9149(90)90562-F

10.1016/0002-9149(90)90566-J

10.1161/01.CIR.79.1.8

10.1056/NEJM199908053410604

10.1185/030079900542849

10.1016/S0002-9149(00)01012-2

10.1016/S0002-9149(97)00965-X

10.1016/S0002-9149(97)00280-4

10.1177/107424840000500104

10.1001/jama.285.19.2486

Timar O, 2000, Metabolic syndrome X: Areview, Can J Cardiol, 16, 779

10.1001/jama.287.3.356

10.1161/hc5001.100624

10.1161/01.CIR.97.18.1837

Thông tin
Thông tin xuất bản

Clinical Cardiology

Tập 26 Số 11

509-514

Thông tin tác giả